
    
      Total study duration for a participant can be up to 28 months.

      This trial is being conducted in countries where the INN designation for the study molecule
      is "aflibercept" and this term is therefore used throughout the synopsis. In the US, the US
      proper name is "ziv-aflibercept".
    
  